Gossamer Bio Inc

For the period ended Dec 31, 2024. Filed Mar 13, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 13, 2025

GOSS$11.28+6.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Year Ended December 31,
	2024	2023	2022
Revenue:
Revenue from sale of licenses	$90,682	$—	$—
Revenue from contracts with collaborators	24,019	—	—
Total revenue	114,701	—	—
Operating expenses:
Research and development	138,487	135,304	170,919
In process research and development	—	10,000	65
General and administrative	36,133	38,455	47,609
Total operating expenses	174,620	183,759	218,593
Loss from operations	(59,919)	(183,759)	(218,593)
Other income (expense)
Interest income	1,779	1,997	1,583
Interest expense	(11,517)	(13,511)	(13,880)
Other income, net	14,022	15,456	1,512
Total other income (expense), net	4,284	3,942	(10,785)
Loss before provision for income taxes	(55,635)	(179,817)	(229,378)
Provision for income taxes	893	—	—
Net loss	$(56,528)	$(179,817)	$(229,378)
Other comprehensive income (loss):
Foreign currency translation	1,450	33	(544)
Unrealized income (loss) on marketable securities	89	191	(75)
Other comprehensive income (loss)	1,539	224	(619)
Comprehensive loss	$(54,989)	$(179,593)	$(229,997)
Net loss per share, basic and diluted	$(0.25)	$(1.18)	$(2.71)
Weighted average common shares outstanding, basic and diluted	226,228,016	152,621,669	84,574,869

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.